The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02093858

Enrollment

212

Registered

2014-03-21

Start date

2014-04-30

Completion date

2017-12-31

Last updated

2014-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Schizophrenia

Keywords

Metabolic Syndrome

Brief summary

Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in the development of antipsychotics-induced metabolic syndrome.

Detailed description

* In this study, we will determine the effect of olanzapine on the expression of TCF7L2 and SLC30A8. * The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced metabolic syndrome in schizophrenia patients.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of first episode schizophrenia * Must be able to swallow tablets * Take only one antipsychotics

Exclusion criteria

* liver or renal or cardiovascular diseases * pregnant or lactating women * drug and alcohol dependence

Design outcomes

Primary

Measure	Time frame
Change in weight and blood glucose	24 weeks

Secondary

Measure	Time frame
Change of the blood pressure and blood lipid	24 weeks

Other

Measure	Time frame
Change of serum insulin	24 weeks

Countries

China

Contacts

Primary ContactRenRong Wu, PhD

wurenrong2013@163.com0731-85554052

Outcome results